Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,517 shares of the biopharmaceutical company’s stock after selling 22,070 shares during the period. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $6,918,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of GILD. Kennedy Capital Management LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at $2,946,000. B. Riley Wealth Advisors Inc. increased its holdings in Gilead Sciences by 2.2% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 28,519 shares of the biopharmaceutical company’s stock valued at $2,137,000 after acquiring an additional 604 shares in the last quarter. Atria Investments Inc increased its holdings in Gilead Sciences by 16.2% during the 1st quarter. Atria Investments Inc now owns 89,515 shares of the biopharmaceutical company’s stock valued at $6,557,000 after acquiring an additional 12,507 shares in the last quarter. Cetera Investment Advisers raised its position in Gilead Sciences by 127.6% during the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after acquiring an additional 119,909 shares during the last quarter. Finally, Cetera Advisors LLC lifted its holdings in shares of Gilead Sciences by 167.2% in the first quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock valued at $6,064,000 after purchasing an additional 51,801 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.2 %

NASDAQ:GILD opened at $92.41 on Thursday. The business’s 50-day moving average is $87.91 and its two-hundred day moving average is $77.42. The firm has a market capitalization of $115.17 billion, a PE ratio of 1,026.78, a price-to-earnings-growth ratio of 2.81 and a beta of 0.17. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 EPS. Research analysts predict that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.33%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,735 shares of company stock worth $5,589,030 over the last ninety days. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Barclays raised their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Cantor Fitzgerald upped their price objective on Gilead Sciences from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Finally, UBS Group upped their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $95.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.